Diabetes mellitus and cystic fibrosis: Comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents

Pediatric Pulmonology

Volumn 32, Issue 5, 2001, Pages 351-355

  Rosenecker, Joseph ^a   Eichler, Irmgard ^a,b   Brmeier, Heike ^a,c,d   Von Der Hardt, Horst ^a,c,d  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cystic fibrosis; Diabetes mellitus; Glibenclamide; Insulin; Natural history; Sulfonylurea

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE COURSE; FEMALE; FORCED EXPIRATORY VOLUME; HEMOGLOBIN DETERMINATION; HUMAN; INTERMETHOD COMPARISON; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME;

CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS;

EID: 0034757695     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.1143     Document Type: Article

References (30)

1. Genetic determination of diabetes mellitus in patients with cystic fibrosis
2. Insulin sensitivity in cystic fibrosis
3. Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycemia in CF
4. Roles of insulin resistance and beta-cell dysfunction in the pathogenesis of glucose intolerance in cystic fibrosis
5. Insulin sensitivity and insulin clearance in CF patients with normal and diabetic glucose tolerance
6. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: A consensus conference report
7. Sulfonylurea in the treatment of CFRD. A 15 year experience
8. Glipizide treatment of patients with CF and impaired glucose tolerance
9. Tolbutamide causes a modest increase in insulin secretion in CF patients with impaired glucose tolerance
10. Glipizide increased insulin secretion but not growth of children with CF
11. Effects of tolbutamide on growth and body composition of nondiabetic children with CF
12. Cystic fibrosis associated islet changes may provide a basis for diabetes. An immunochemical and morphometric study
13. Endocrine pancreas in cystic fibrosis: An immunohistochemical study
14. Insulin resistance is associated with decreased clinical status in cystic fibrosis
15. Insulin sensitivity in cystic fibrosis
16. Pancreatic endocrine function in cystic fibrosis
17. Pancreatic alpha and beta function in cystic fibrosis
18. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance
19. Beta cell function, peripheral sensitivity to insulin and islet cell auto immunity in cystic fibrosis patients with normal glucose tolerance
20. First-phase insulin release in adult cystic fibrosis patients: Correlation with clinical and biological parameters
21. Diagnosis of diabetes mellitus in cystic fibrosis and thalassemia major
22. Insulin resistance with altered secretory kinetics and reduced proinsulin in cystic fibrosis (CF) patients
23. Cystic fibrosis-related diabetes: An approach to diagnosis and management
24. Correlation between genotype and phenotype in patients with cystic fibrosis
25. The effect of the frequency of the ΔF 508 mutation on the course of pulmonary disease in cystic fibrosis patients infected with Pseudomonas aeruginosa
26. Cloning of the β-cell high-affinity sulfonylurea receptor: A regulator of insulin secretion
27. Glibenclamide blockade of CFTR chloride channles
28. Diabetes mellitus in cystic fibrosis: Effect of insulin therapy on lung function and infections
29. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline